Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants.

[1]  S. Connolly,et al.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. , 2015, The New England journal of medicine.

[2]  T. Villines,et al.  A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system , 2015, Thrombosis and Haemostasis.

[3]  S. Glund,et al.  Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial , 2015, The Lancet.

[4]  T. Steiner,et al.  Idarucizumab for Dabigatran Reversal. , 2015, The New England journal of medicine.

[5]  J. Weitz,et al.  Overview of the new oral anticoagulants: opportunities and challenges. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[6]  A. Greinacher,et al.  Reversal of anticoagulants: an overview of current developments , 2015, Thrombosis and Haemostasis.

[7]  M. Monreal,et al.  Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism , 2015, Journal of cardiovascular pharmacology and therapeutics.

[8]  S. Glund,et al.  A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran , 2015, Thrombosis and Haemostasis.

[9]  S. Bakhru,et al.  PER977 REVERSES LOW MOLECULAR WEIGHT HEPARIN IN ADDITION TO IIA AND XA NEW ORAL ANTICOAGULANTS , 2015 .

[10]  Y. Mo,et al.  Recent Advances in the Development of Specific Antidotes for Target‐Specific Oral Anticoagulants , 2015, Pharmacotherapy.

[11]  G. Lip,et al.  Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. , 2015, International journal of cardiology.

[12]  W. Frank Peacock,et al.  Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban , 2015, Clinical cardiology.

[13]  Mark Levenson,et al.  Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation , 2015, Circulation.

[14]  S. Connolly,et al.  A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors , 2014 .

[15]  S. Glund,et al.  Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects , 2014 .

[16]  J. Ansell,et al.  Use of PER977 to reverse the anticoagulant effect of edoxaban. , 2014, The New England journal of medicine.

[17]  R. Wadhera,et al.  Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose? , 2014, Circulation.

[18]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[19]  H. Masumoto,et al.  Abstract 18809: PER977: A Synthetic Small Molecule Which Reverses Over-Dosage and Bleeding by the New Oral Anticoagulants , 2013, Circulation.

[20]  S. Connolly,et al.  A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors , 2013 .

[21]  A. Shenker,et al.  Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. , 2013, British journal of clinical pharmacology.

[22]  C. Pollack.  Managing bleeding in anticoagulated patients in the emergency care setting. , 2013, The Journal of emergency medicine.

[23]  G. Raskob,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[24]  D. Atar,et al.  Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .

[25]  G. Raskob,et al.  Edoxaban for the long‐term treatment of venous thromboembolism: rationale and design of the Hokusai‐venous thromboembolism study – methodological implications for clinical trials , 2013, Journal of thrombosis and haemostasis : JTH.

[26]  D. Lillicrap.  Translational medicine advances in von Willebrand disease , 2013, Journal of thrombosis and haemostasis : JTH.

[27]  L. Harinstein,et al.  Treatment of Dabigatran-Associated Bleeding , 2013, Journal of pharmacy practice.

[28]  H. Nar,et al.  A specific antidote for dabigatran: functional and structural characterization. , 2013, Blood.

[29]  P. Conley,et al.  A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa , 2013, Nature Medicine.

[30]  W. Dager,et al.  Removal of dabigatran by hemodialysis. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  D. Siegal,et al.  Acute management of bleeding in patients on novel oral anticoagulants. , 2013, European heart journal.

[32]  H. Masumoto,et al.  Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans , 2012, Drug Metabolism and Disposition.

[33]  S. Kitchen,et al.  Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study , 2012, The Annals of pharmacotherapy.

[34]  E. Mathiowitz,et al.  Abstract 11395: Small Molecule Antidote for Anticoagulants , 2012 .

[35]  R. Stafford,et al.  National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011 , 2012, Circulation. Cardiovascular quality and outcomes.

[36]  Marta a. Miyares,et al.  Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[37]  E. Truumees,et al.  Epidural Hematoma and Intraoperative Hemorrhage in a Spine Trauma Patient on Pradaxa (Dabigatran) , 2012, Spine.

[38]  J. Douketis,et al.  Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors , 2012, American journal of hematology.

[39]  Marta a. Miyares,et al.  Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. , 2012, The American journal of geriatric pharmacotherapy.

[40]  C. Richards,et al.  Emergency Hospitalization for Adverse Drug Events in Older Americans , 2012 .

[41]  W. Chandler,et al.  Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. , 2012, American journal of clinical pathology.

[42]  E. Merriman,et al.  Bleeding risk with dabigatran in the frail elderly. , 2012, The New England journal of medicine.

[43]  Mark Crowther,et al.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[44]  J. Holcomb,et al.  Acutely injured patients on dabigatran. , 2011, The New England journal of medicine.

[45]  C. Richards,et al.  Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.

[46]  P. Prandoni,et al.  Erratum to: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention , 2011, Clinical Pharmacokinetics.

[47]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[48]  M. Legrand,et al.  The use of dabigatran in elderly patients. , 2011, Archives of internal medicine.

[49]  Lesly A. Dossett,et al.  Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. , 2011, Archives of surgery.

[50]  John Camm,et al.  Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[51]  M. Fornage,et al.  Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[52]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[53]  T. Lindahl,et al.  Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays , 2010, Thrombosis and Haemostasis.

[54]  A. Shenker,et al.  Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay , 2010, Thrombosis and Haemostasis.

[55]  H. Masumoto,et al.  Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers , 2010, Journal of clinical pharmacology.

[56]  K. Rathgen,et al.  Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate , 2010, Clinical pharmacokinetics.

[57]  Elisabeth Perzborn,et al.  Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor , 2010, Thrombosis and Haemostasis.

[58]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[59]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[60]  C. Weinz,et al.  Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans , 2009, Drug Metabolism and Disposition.

[61]  W. Humphreys,et al.  Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans , 2009, Drug Metabolism and Disposition.

[62]  D. Cines,et al.  Interlaboratory agreement in the monitoring of unfractionated heparin using the anti‐factor Xa‐correlated activated partial thromboplastin time , 2009, Journal of thrombosis and haemostasis : JTH.

[63]  P. Lam,et al.  Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies , 2008, Journal of thrombosis and haemostasis : JTH.

[64]  T. Ebner,et al.  The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans , 2008, Drug Metabolism and Disposition.

[65]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[66]  D. Wysowski,et al.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.

[67]  Michael Becka,et al.  Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects , 2005, European Journal of Clinical Pharmacology.

[68]  N. Holford.  Clinical Pharmacokinetics and Pharmacodynamics of Warfarin , 1986, Clinical pharmacokinetics.

[69]  C. Wiedermann,et al.  Warfarin-induced bleeding complications - clinical presentation and therapeutic options. , 2008, Thrombosis research.